Regulatory Divergence HEOR Impacts

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: transatlantic regulatory divergence, ADC portfolio implications, NICE reversal on MRD endpoints, and cross-jurisdictional regulatory crises. Let's get into it.

MarcusThe camizestrant transatlantic divergence is a case study in regulatory fragmentation. The FDA and EMA are sending conflicting signals, creating HEOR evidence gaps. We're seeing divergent efficacy endpoints and safety profiles being prioritized differently. This forces HEOR teams to develop separate dossiers, increasing resource strain and delaying access.

SaraBut Marcus, is it really about the evidence gaps? I see this as a commercial strategy issue. The divergence is being exploited to extend market exclusivity in one region while the other catches up. The HEOR narrative is being tailored to fit each regulator's preferences, not because of true scientific differences. It's a strategic maneuver.

MarcusThat's oversimplifying. The regulatory pathways are fundamentally different. The FDA's accelerated approval vs. EMA's conditional approval creates different evidence requirements. HEOR can't just mirror regulatory strategies; it must address the actual evidence needs for each market.

SaraBut the HEOR community is being pulled into commercial tactics. We're seeing companies use regulatory divergence to justify higher prices in one jurisdiction by pointing to the other's approval. That's not evidence-driven; it's commercial leverage. The HEOR evidence is being weaponized.

MarcusThe evidence is still the foundation. Without solid data, the commercial arguments fall apart. HEOR must remain anchored in real-world evidence, not regulatory arbitrage.

MarcusThe interim CDF recommendation for mirvetuximab soravtansine signals a shift in ADC assessment. The CDF is accepting surrogate endpoints, which could accelerate access for ADCs. This has portfolio implications for other ADCs in development, as the benchmark for evidence acceptance is moving.

SaraBut Marcus, is this a sustainable shift? The CDF's interim recommendation is based on limited data. We're setting a precedent for accelerated access based on surrogate endpoints, which may not hold up in long-term outcomes. This could create a bubble of approvals that later collapse, leaving HEOR teams to clean up the mess.

MarcusThe CDF is designed for innovative technologies. ADCs are complex, and traditional endpoints may not capture their value. The interim approach is pragmatic, allowing earlier access while real-world evidence accumulates. HEOR can adapt by designing studies that capture long-term benefits.

SaraThe problem is the portfolio implications. Companies are now rushing to develop ADCs with surrogate endpoints to hit the CDF window, without robust evidence. This could flood the market with therapies of uncertain value, forcing HEOR to defend or refute their effectiveness later. It's a risky strategy.

MarcusThe market will sort it out. If the ADCs deliver, they'll gain traction. If not, they'll be withdrawn. HEOR's role is to provide the evidence for that decision, not to pre-empt it.

MarcusThe NICE reversal on D-VRd and the acceptance of MRD as a cost-effectiveness endpoint is a game-changer. It reflects a shift towards minimal residual disease as a surrogate for long-term survival. This could accelerate access for multiple myeloma therapies, as the endpoint is more responsive to treatment effects.

SaraBut Marcus, is MRD a reliable cost-effectiveness endpoint? The evidence base is still maturing. NICE's reversal might be premature, setting a precedent that could lead to approvals based on surrogate endpoints without proven long-term cost-effectiveness. This could strain health systems if the benefits don't materialize.

MarcusNICE is adapting to scientific advances. MRD is a validated endpoint in myeloma, and the reversal indicates a willingness to use it when appropriate. HEOR can model the cost-effectiveness using MRD data, especially when combined with other evidence.

SaraThe commercial framing is problematic. Companies will now prioritize MRD as a go-to endpoint to get NICE approvals, potentially at the expense of generating real-world evidence. This could lead to a reliance on surrogates that don't translate to real-world value. HEOR must resist this trend.

MarcusThe evidence is there. MRD correlates with survival, and the models are robust. HEOR should embrace this shift, not resist it.

MarcusThe avacopan cross-jurisdictional regulatory crisis highlights the fragility of global evidence strategies. Safety concerns in one region are causing access delays in others, even where the data is favorable. HEOR teams must now navigate patchworks of regulatory decisions, creating significant uncertainty.

SaraThis is more than a regulatory issue; it's a communication crisis. The lack of harmonized safety assessments is leading to inconsistent messaging, which affects both prescriber and payer confidence. HEOR must step in to provide clarity, but the evidence is being interpreted differently across jurisdictions.

MarcusThe HEOR challenge is to aggregate data from multiple regions to build a unified evidence package. This requires sophisticated meta-analyses and real-world evidence to bridge the gaps. Without it, access will remain fragmented.

SaraThe commercial impact is substantial. Companies are facing reimbursement delays and price negotiations based on regional safety concerns. HEOR must address these concerns head-on, but the data is often inconclusive, leading to stalemates.

MarcusThe key is transparency. HEOR should present all available data, including regional variations, to inform decision-makers. This builds trust and reduces uncertainty.

MarcusRegulatory divergence, ADC implications, NICE reversals, and cross-jurisdictional crises — these are the challenges shaping HEOR strategies today.

SaraAnd tomorrow, the landscape will shift again. Staying ahead requires agility and a relentless focus on evidence.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.